Literature DB >> 22410712

Recurrence after surgical resection of gastrinoma: who, when, where and why?

Frédérique Maire1, Alain Sauvanet, Anne Couvelard, Vinciane Rebours, Marie-Pierre Vullierme, Rachida Lebtahi, Olivia Hentic, Jacques Belghiti, Pascal Hammel, Philippe Lévy, Philippe Ruszniewski.   

Abstract

BACKGROUND: Surgery prolongs survival in patients with gastrinomas, but postoperative recurrences are frequent and controversies still exist about the optimal surgical procedures. AIM: The aim of this study is to analyze biological and morphological recurrences and to search for risk factors. PATIENTS AND METHODS: Between 1990 and 2008, 22 patients (five with multiple endocrine neoplasia type 1) who underwent curative resection for gastrinoma were evaluated every 6 months for biological and morphological recurrences. All patients were disease-free postresection.
RESULTS: The median postoperative follow-up was 37 months (range, 7-204 months). A biological recurrence was observed in 59% of cases, after a median time of 16.5 months (range, 7-90 months). A morphological recurrence was reported in 32% of cases, in the liver (86%) or lymph nodes (43%), after a median time of 21 months (range, 8-91 months). The median delay between biological and morphological recurrence was 3 months (range, 0-69 months). At recurrence, all patients were offered a second treatment (surgical resection in 71% of cases). One and 5 year overall survival were 100 and 76%, respectively. One and 5 year biological disease-free survival (DFS) were 76 and 27%, respectively. One and 5 year morphological DFS were 90 and 62%, respectively. Tumor size of at least 20 mm (P=0.008) and pancreatic location (P=0.04) of the primary tumor had significant effect on morphological DFS. Overall survival was significantly lower in patients with primary tumor of at least 20 mm (P=0.01).
CONCLUSION: (a) Recurrence occurs in nearly two out of three patients operated upon for gastrinoma, most often detected through biological tests; (b) lymph nodes and liver are the most frequent sites of relapse and patients benefit from second treatment; (c) risk factors for recurrences are as follows: size of at least 20 mm; and the pancreatic location of the primary tumor.

Entities:  

Mesh:

Year:  2012        PMID: 22410712     DOI: 10.1097/MEG.0b013e328350f816

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

1.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 2.  The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

Authors:  Valentina Guarnotta; Chiara Martini; Maria Vittoria Davì; Genoveffa Pizza; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2017-10-10       Impact factor: 3.633

3.  Comparison study of gastrinomas between gastric and non-gastric origins.

Authors:  Song-Fong Huang; I-Ming Kuo; Chao-Wei Lee; Kuang-Tse Pan; Tse-Ching Chen; Chun-Jung Lin; Tsann-Long Hwang; Ming-Chin Yu
Journal:  World J Surg Oncol       Date:  2015-06-16       Impact factor: 2.754

4.  Diagnosis and prediction of neuroendocrine liver metastases: a protocol of six systematic reviews.

Authors:  Stephan Arigoni; Stefan Ignjatovic; Patrizia Sager; Jonas Betschart; Tobias Buerge; Josephine Wachtl; Christoph Tschuor; Perparim Limani; Milo A Puhan; Mickael Lesurtel; Dimitri A Raptis; Stefan Breitenstein
Journal:  JMIR Res Protoc       Date:  2013-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.